Dr. Hamid on the Evolution of Precision Medicine in Prostate Cancer

Partner | Cancer Centers | <b>Dana Farber</b>

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the evolution of precision medicine in prostate cancer.

It is exciting to see precision medicine truly take hold in prostate cancer, says Hamid. Historically, clinically driven parameters such as volume of metastatic disease were used to indicate which subpopulations of patients benefit from chemotherapy versus those that do not. Now, the field can use biological parameters to guide more precise treatment decisions.

Precision medicine is becoming more apparent across oncology with the use of clinical information, biological information, and drug response information, among other things, concludes Hamid.